The Technical Analyst
[]
Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.22% 31.29
/
| RATING 2022-03-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/18 | 4/18 | 3/19 | 4/19 | 3/20 | 4/20 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
1.439 - 1.881 ( +/- 13.31%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-04-01 | Mazzo David J | Buy | 6 000 | Restricted Stock Units |
| 2021-04-01 | Gray Mary Ann | Buy | 6 000 | Restricted Stock Units |
| 2021-04-01 | Csimma Cristina | Buy | 6 000 | Restricted Stock Units |
| 2021-04-01 | Wei Binxian | Buy | 6 000 | Restricted Stock Units |
| 2020-04-03 | Wei Binxian | Buy | 6 000 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 0.00 |
| Last 8 transactions |
| Buy: 48 000 | Sell: 0 |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | 31.29 (-0.22% ) |
| Volume | 0.0001 mill |
| Avg. Vol. | 0.0011 mill |
| % of Avg. Vol | 11.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
Latest Press Releases
2021-04-26 07:00:00 - Press Release
Seneca Biopharma Announces Successful Approval Of Merger With Leading Biosciences, Inc.
Germantown, md., april 26, 2021 /prnewswire/ -- seneca biopharma, inc. (nasdaq: snca) ("seneca" or the "company"), disclosed on april 23, 2021, the passing of the final proposal required for approval of the proposed merger between seneca and leading biosciences, inc. ("lbs").
2021-04-12 07:00:00 - Press Release
Seneca Biopharma, Inc. Announces (i) Voting Results From The Special Meeting Of Stockholders And (ii) New Special Meeting Date Of April 23, 2021
Germantown, md., april 12, 2021 /prnewswire/ -- seneca biopharma, inc. (nasdaq: snca) ("seneca" or the "company"), announced the preliminary voting results of its special meeting of stockholders on april 9, 2021.
2021-04-02 11:35:00 - Press Release
Leading Biosciences Releases Video Message Highlighting Compelling Investment Thesis Of Proposed Merger With Seneca Biopharma, Inc.
Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named palisade bio
2021-03-24 16:30:00 - Press Release
Seneca Announces New Special Meeting Date Of April 9, 2021
Germantown, md., march 24, 2021 /prnewswire/ -- seneca biopharma, inc. (nasdaq: snca) (the "company") today announced that the company adjourned its special meeting of stockholders scheduled for wednesday, march 24, 2021 at 11:00 a.m.
2021-03-22 20:08:00 - Press Release
Seneca Biopharma Reports 2020 Yearend Results
Germantown, md., march 22, 2021 /prnewswire/ -- seneca biopharma, inc. (nasdaq: snca), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today reported its financial results for the year ended december 31, 2020.
Latest News
2021-04-26 07:00:00 - PRNewsWire
Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.
GERMANTOWN, Md., April 26, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of the proposed merger between Seneca and Leading Biosciences, Inc. ("LBS").
2021-04-20 09:12:14 - Benzinga
Seneca Biopharma's Merger Partner Leading BioSciences' Lead Asset Shows Efficacy In Lower Post-Surgical Adhesions
Privately-held Leading BioSciences Inc entered into a definitive agreement for a reverse merger with Seneca Biopharma Inc (NASDAQ: SNCA) has announced data from an open-label gastrointestinal (GI) surgery study with lead asset LB1148. Data provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection.
2021-04-12 07:00:00 - PRNewsWire
Seneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Meeting Date of April 23, 2021
GERMANTOWN, Md., April 12, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on April 9, 2021.
2021-04-05 04:27:21 - Pulse2
Seneca Biopharma Stock Price Increased Over 20% Pre-Market: Why It Happened
The stock price of Seneca Biopharma Inc (NASDAQ: SNCA) increased by over 20% pre-market. This is why it happened.
2021-04-02 11:35:00 - GlobeNewsWire
Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.
Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio
2021-03-24 16:30:00 - PRNewsWire
Seneca Announces New Special Meeting Date of April 9, 2021
GERMANTOWN, Md., March 24, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) (the "Company") today announced that the Company adjourned its special meeting of stockholders scheduled for Wednesday, March 24, 2021 at 11:00 a.m.
2021-03-23 07:14:36 - Pulse2
SNCA Stock Price Falls Over 4% Pre-Market: Why It Happened
The stock price of Seneca Biopharma Inc (NASDAQ: SNCA) fell by over 4% pre-market. This is why it happened.
2021-03-22 20:08:00 - PRNewsWire
Seneca Biopharma Reports 2020 Yearend Results
GERMANTOWN, Md., March 22, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today reported its financial results for the year ended December 31, 2020.
2021-03-22 14:31:41 - InvestorPlace
SNCA Stock: Seneca Biopharma Shares Rocket Ahead of Merger, Reverse Stock Split Meeting
Seneca Biopharma (SNCA) stock is on the rise as investors prepare for an upcoming meeting covering a merger and reverse stock split. The post SNCA Stock: Seneca Biopharma Shares Rocket Ahead of Merger, Reverse Stock Split Meeting appeared first on InvestorPlace.
2021-03-22 06:04:38 - Pulse2
SNCA Stock Price Increases Over 80% Pre-Market: Why It Happened
The stock price of Seneca Biopharma Inc (NASDAQ: SNCA) has increased by over 80% during pre-market trading. This is why it happened.